专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO1994022845A1 BENZOTHIAZOLE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF 审中-公开
标题翻译：苯并噻唑化合物，其生产方法及其用途
公开(公告)号：WO1994022845A1
公开(公告)日：1994-10-13
申请号：PCT/JP1994000490
申请日：1994-03-25
申请人： SENJU PHARMACEUTICAL CO., LTD. , THE GREEN CROSS CORPORATION , HASE, Takema , KUMONAKA, Takahiro , SHIMIZU, Chikako , HOSONO, Hiroshi , AOTSUKA, Tomoji , NAKAMURA, Yoshiyuki , MATSUI, Tetsuo , ISHIKAWA, Hiromichi
发明人： SENJU PHARMACEUTICAL CO., LTD. , THE GREEN CROSS CORPORATION
IPC分类号： C07D277/64
CPC分类号： C07C255/25 , C07D277/64
摘要： A benzothiazole compound represented by general formula (I) and a pharmaceutically acceptable salt thereof wherein, R represents halogen; R and R represent each independently hydrogen or halogen; R represents hydrogen, halogen, lower alkyl, alkoxy or alkylmercapto; and R represents hydrogen or lower alkyl. The compound (I) and salt thereof have an aldose reductase inhibitor activity against mammals including human and is excellent in safety. Therefore they are useful as remedies for treating complications of diabetes, such as defective union of injured cornea, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis.
摘要翻译：由通式（I）表示的苯并噻唑化合物及其药学上可接受的盐，其中R 1表示卤素; R 2和R 3各自独立地表示氢或卤素; R 4表示氢，卤素，低级烷基，烷氧基或烷基巯基; R 5表示氢或低级烷基。化合物（I）及其盐具有对包括人类的哺乳动物的醛糖还原酶抑制剂活性，并且安全性优异。因此，它们可用作治疗糖尿病并发症的补救措施，例如受损的角膜联合不良，白内障，神经症，视网膜病变和肾病，特别是白内障和神经症。

12. 发明申请

WO1994017058A1 IMIDAZOLE COMPOUND 审中-公开
标题翻译：咪唑化合物
公开(公告)号：WO1994017058A1
公开(公告)日：1994-08-04
申请号：PCT/JP1993001822
申请日：1993-12-15
申请人： THE GREEN CROSS CORPORATION , YANAI, Kzuhiko , WATANABE, Takehiko , GOTOH, Tomokazu , SAKASHITA, Hiroshi , MURAKAMI, Kazuki , SUGIURA, Masanori , FUKAYA, Chikara
发明人： THE GREEN CROSS CORPORATION
IPC分类号： C07D401/04
CPC分类号： C07D401/04
摘要： The invention aims at providing a novel compound having vitamin H3 receptor antagonism and relates to a compound represented by general formula (O) or pharmaceutically acceptable salts thereof, wherein m represents an integer of 4 to 6; R1 represents hydrogen, lower alkyl or aralkyl; R2 and R3 may be the same or different from each other and each represents hydrogen or lower alkyl; R4 represents hydrogen, linear or branched alkyl, cycloalkyl, cycloalkylalkyl, optionally substituted aryl, or optionally substituted aralkyl; Z represents R5 or A-R6; A represents S or O; R5 represents hydrogen, lower alkyl, optionally substituted aryl, or optionally substituted aralkyl; and R6 represents lower alkyl, lower alkenyl, lower alkynyl, or optionally substituted aralkyl.
摘要翻译：本发明旨在提供一种具有维生素H3受体拮抗作用的新化合物，涉及由通式（O）表示的化合物或其药学上可接受的盐，其中m表示4至6的整数; R1代表氢，低级烷基或芳烷基; R2和R3可以相同或不同，各自代表氢或低级烷基; R 4表示氢，直链或支链烷基，环烷基，环烷基烷基，任选取代的芳基或任选取代的芳烷基; Z表示R5或A-R6; A表示S或O; R5表示氢，低级烷基，任选取代的芳基或任选取代的芳烷基; 并且R 6表示低级烷基，低级烯基，低级炔基或任选取代的芳烷基。

13. 发明申请

WO1994012499A1 1,8-NAPHTHYRIDIN-2-ONE DERIVATIVE AND USE THEREOF_ 审中-公开
标题翻译： 1,8-萘啶-2-酮衍生物及其用途
公开(公告)号：WO1994012499A1
公开(公告)日：1994-06-09
申请号：PCT/JP1992001575
申请日：1992-12-01
申请人： THE GREEN CROSS CORPORATION , MATSUURA, Akihiro , ASHIZAWA, Naoki , HASE, Takema
发明人： THE GREEN CROSS CORPORATION
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： A 1,8-naphthyridin-2-one derivative, a pharmaceutically acceptable acid addition salt thereof, and a remedy containing the same as an active ingredient for treating various diseases including peripheral diseases such as hypertension, renal failure, heart failure, angina pectoris, myocardial infarction and peripheral circulatory disturbance, diseases of circulatory and respiratory systems such as arteriosclerosis, obstructive thromboangiitis, aortitis syndrome and bronchial asthma, central nervous system diseases such as depression, hypofunction of central nervous system after cerebrovascular obstruction, cerebrovascular dementia, senile dementia, Alzheimer disease and disturbance of memory and learning functions, various inflammations, and obesity.
摘要翻译： 1,8-萘啶-2-酮衍生物，其药学上可接受的酸加成盐，以及含有其作为活性成分的治疗剂，用于治疗各种疾病，包括高血压，肾功能衰竭，心力衰竭，心绞痛，心肌梗死和周围循环障碍，循环系统和呼吸系统疾病如动脉硬化，阻塞性血管炎，主动脉炎综合征和支气管哮喘，中枢神经系统疾病如抑郁症，脑血管阻塞后中枢神经系统功能低下，脑血管性痴呆，老年痴呆，阿尔茨海默病疾病和记忆障碍和学习功能，各种炎症和肥胖。

14. 发明申请

WO1992009303A1 ALBUMIN PREPARATION AND PRESERVATION THEREOF 审中-公开
标题翻译：铝制备和保存
公开(公告)号：WO1992009303A1
公开(公告)日：1992-06-11
申请号：PCT/JP1991001675
申请日：1991-11-29
申请人： THE GREEN CROSS CORPORATION , INOUE, Masahiro , ITO, Hirokazu , TOMIOKA, Shinji , YABUSHITA, Sadao , IKARIYA, Koei , FURUTA, Koichi
发明人： THE GREEN CROSS CORPORATION
IPC分类号： A61K37/04
CPC分类号： C07K14/76 , Y10S215/03
摘要： A highly safe albumin preparation which can be preserved while preventing the release of aluminum from the container to thereby keep the aluminum content very low, by preserving an aqueous albumin solution in a soft glass container dealkalized by treating with, for example, sulfur dioxide gas or an ammonium sulfate solution instead of the conventional hard glass container which releases aluminum which has been believed to cause various diseases such as dialysis dementia, bone diseases, hypochromic anemia or Alzheimer's disease.

15. 发明申请

WO1990011278A1 THIAZOLE COMPOUNDS AND APPLICATIONS THEREOF 审中-公开
标题翻译：噻唑化合物及其应用
公开(公告)号：WO1990011278A1
公开(公告)日：1990-10-04
申请号：PCT/JP1990000385
申请日：1990-03-22
申请人： THE GREEN CROSS CORPORATION , GOTO, Tomokazu; , OKANO, Tadashi; , SUGIYAMA, Naoki; , AKABOSHI, Fumihiko; , ONO, Shinichiro; , NAITO, Yoichiro; , YAMAURA, Yasunari; , FUKAYA, Chikara; , YOKOYAMA, Kazumasa;
发明人： THE GREEN CROSS CORPORATION
IPC分类号： C07D277/20
CPC分类号： C07D277/22 , C07D277/24 , C07D277/34 , C07D277/56 , C07D277/60
摘要： The invention provides thiazole compounds and pharmacologically acceptable salts thereof excellent in analgesic, antiinflammatory and antipyretic activities, represented by general formula (I), wherein R and R represent each independently hydrogen, halogen, alkyl, alkenyl, nitro, CF3, phenyl, substituted phenyl, pyridyl, substituted pyridyl, carboxyl, alkoxycarbonyl, -CONR R (wherein R and R represent each hydrogen or alkyl), acyl, hydroxy, alkoxy or thioalkyl, or alternatively R and R are combined together to form -(CH2)m- (wherein m is 3 to 5); R represents hydrogen or alkyl; R represents hydroxy, alkoxy or -NR R (wherein R and R represent each hydrogen or alkyl); X represents carbonyl or -(CH2)n- (wherein n is 0 or 1); and Y represents hydrogen, halogen, alkyl, nitro, CF3, -NR R (wherein R and R represent each hydrogen or alkyl), hydroxy (only when the position of X is para to the CHR COR group), alkoxy (only when the position of X is para to the CHR COR group), or alkylthio.
摘要翻译：本发明提供了由通式（I）表示的止痛，抗炎和解热活性优异的噻唑化合物及其药理学上可接受的盐，其中R 1和R 2各自独立地表示氢，卤素，烷基，链烯基，硝基， CF 3，苯基，取代的苯基，吡啶基，取代的吡啶基，羧基，烷氧基羰基，-CONR 5 R 6（其中R 5和R 6各自代表氢或烷基），酰基，羟基，烷氧基或硫代烷基或者R 1和R 2组合在一起形成 - （CH 2）m - （其中m为3至5）; R 3表示氢或烷基; R 4表示羟基，烷氧基或-NR 7 R 8（其中R 7和R 8表示各自的氢或烷基）。 X表示羰基或 - （CH 2）n - （其中n为0或1）; 和Y表示氢，卤素，烷基，硝基，CF 3，-NR 9 R 10（其中R 9和R 10表示各自的氢或烷基），羟基（仅当X的位置为对至CHR 3 COR 4基团），烷氧基（仅当X的位置对于CHR 3 COR 4基团时）或烷硫基。

16. 发明申请

WO2021096241A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开
公开(公告)号：WO2021096241A1
公开(公告)日：2021-05-20
申请号：PCT/KR2020/015871
申请日：2020-11-12
申请人： YUHAN CORPORATION , GREEN CROSS CORPORATION
发明人： KIM, Dong-Hoon , JOO, Jae-Eun , LEE, Eui-Chul , HAN, Tae-Dong , SHIN, Seung-Yub , KWON, Sool-Ki
IPC分类号： C07D471/08 , A61K31/439 , A61P25/16 , A61P43/00
摘要： The present invention provides a novel compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

17. 发明申请

WO2021096239A1 NOVEL DERIVATIVES HAVING 1,2,3,4-TETRAHYDRONAPHTHALENE MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开
公开(公告)号：WO2021096239A1
公开(公告)日：2021-05-20
申请号：PCT/KR2020/015867
申请日：2020-11-12
申请人： YUHAN CORPORATION , GREEN CROSS CORPORATION
发明人： KIM, Dong-Hoon , JOO, Jae-Eun , LEE, Eui-Chul , HAN, Tae-Dong , SHIN, Seung-Yub , KWON, Sool-Ki , KONG, Young-Gyu , MA, Sang-Ho , SON, Ick-Hwan
IPC分类号： C07D471/08 , A61K31/439 , A61P25/16 , A61P43/00
摘要： The present invention provides a novel compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

18. 发明申请

WO2021096238A1 NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开
公开(公告)号：WO2021096238A1
公开(公告)日：2021-05-20
申请号：PCT/KR2020/015864
申请日：2020-11-12
申请人： YUHAN CORPORATION , GREEN CROSS CORPORATION
发明人： KIM, Dong-Hoon , JOO, Jae-Eun , LEE, Eui-Chul , HAN, Tae-Dong , SHIN, Seung-Yub , KWON, Sool-Ki , KIM, Ji-Hye
IPC分类号： C07D471/08 , A61K31/439 , A61P25/16 , A61P43/00
摘要： The present invention provides a novel compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

19. 发明申请

WO2018174629A1 ANTI-CEACAM1 ANTIBODY AND USE THEREOF 审中-公开
公开(公告)号：WO2018174629A1
公开(公告)日：2018-09-27
申请号：PCT/KR2018/003419
申请日：2018-03-23
申请人： MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH , GREEN CROSS CORPORATION
发明人： EUN, So-Young , OH, Miyoung , PARK, Hye-Young , LEE, Mijung , YOON, Aerin , YUM, Hye In , NAM, Hyemi , LEE, Eunhee , WON, Jongwha
IPC分类号： C07K16/28 , A61K39/395 , A61K35/17 , A61K39/39 , A61K39/00
摘要： The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.

20. 发明申请

WO2011159067A2 THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 审中-公开
标题翻译：作为SGLT2抑制剂和包含其的药物组合物的噻唑衍生物
公开(公告)号：WO2011159067A2
公开(公告)日：2011-12-22
申请号：PCT/KR2011/004273
申请日：2011-06-10
申请人： GREEN CROSS CORPORATION , LEE, Jinhwa , KIM, Jeongmin , LEE, Suk Ho , LEE, Junwon , SONG, Kwang-Seop , PARK, Eun-Jung , KIM, Min Ju , SEO, Hee Jeong , LEE, Sung-Han , SON, Eun Jung , KIM, Jong Yup , KANG, Suk Youn , KONG, Younggyu
发明人： LEE, Jinhwa , KIM, Jeongmin , LEE, Suk Ho , LEE, Junwon , SONG, Kwang-Seop , PARK, Eun-Jung , KIM, Min Ju , SEO, Hee Jeong , LEE, Sung-Han , SON, Eun Jung , KIM, Jong Yup , KANG, Suk Youn , KONG, Younggyu
IPC分类号： C07D417/14 , C07D309/10 , C07D417/10 , A61K31/427 , A61K31/351 , A61P3/10
CPC分类号： C07H7/04 , C07D309/10 , C07D417/10 , C07D417/14 , C07D493/10 , C07H17/02
摘要： The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
摘要翻译：本发明涉及一种具有对存在于肠和肾中的钠依赖性葡萄糖协同转运蛋白2（SGLT2）具有抑制活性的噻唑环的新型化合物，以及包含其作为活性成分的药物组合物，其可用于预防或治疗代谢紊乱，特别是糖尿病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式